Zenagamtide versus semaglutide for blood sugar and weight in type 2 diabetes
Compares zenagamtide with semaglutide in adults with type 2 diabetes taking metformin or SGLT2i.
Plain-language title generated from the registry record
Registry title: A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or Both
Key facts
- Where
- Albany, Aurora, Canton, Chesterfield, Chicago, City of Saint Peters, Conyers, Fleming Island, Flint, Greer, Hollywood, Houston, Jacksonville, Katy, Kingsport, La Jolla, Lancaster, Las Vegas, Lincoln, Miami, Mt. Dora, Nashua, Nashville, Newport News, Newton, Olney, Palm Springs, Rockville, San Antonio, Sandy City, Sioux Falls, Statesville, Tampa, West Des Moines, West Seneca, Westfield, and Weston, United StatesSee the 41 sites
- Phase
- Phase 3
Where in United States
- AMC Community EndocrinologyAlbany, United StatesContact: Novo NordiskNo longer taking part
- UC Anschutz Medical CampusAurora, United StatesContact: Novo NordiskNo longer taking part
- Diab & Endo Assoc of Stark CoCanton, United StatesContact: Novo NordiskNo longer taking part
- Diabetes & Endo Specialists IncChesterfield, United StatesContact: Novo NordiskNo longer taking part
- Cedar Crosse Research CenterChicago, United StatesContact: Novo NordiskNo longer taking part
- StudyMetrix Research, LLCCity of Saint Peters, United StatesContact: Novo NordiskNo longer taking part
- Hope Clin Res & WellnessConyers, United StatesContact: Novo NordiskNo longer taking part
- Northeast Research InstituteFleming Island, United StatesContact: Novo NordiskNo longer taking part
- Elite Clinical Research CenterFlint, United StatesContact: Novo NordiskNo longer taking part
- Tribe Clinical Research LLCGreer, United StatesContact: Novo NordiskNo longer taking part
- Encore Medical Research LLCHollywood, United StatesContact: Novo NordiskNo longer taking part
- Southwest Clinical TrialsHouston, United StatesContact: Novo NordiskNo longer taking part
- Victorium Clinical ResearchHouston, United StatesContact: Novo NordiskNo longer taking part
- Northeast Research InstituteJacksonville, United StatesContact: Novo NordiskNo longer taking part
- University of Florida College of Medicine JacksonvilleJacksonville, United StatesContact: Novo NordiskNo longer taking part
- Medical Colleagues-Texas LLPKaty, United StatesContact: Novo NordiskNo longer taking part
- Holston Medical Group.Kingsport, United StatesContact: Novo NordiskNo longer taking part
- Scripps Whittier Diabetes InstLa Jolla, United StatesContact: Novo NordiskNo longer taking part
- First Valley Medical GroupLancaster, United StatesContact: Novo NordiskNo longer taking part
- Palm Research Center Inc-VegasLas Vegas, United StatesContact: Novo NordiskNo longer taking part
- Headlands Research CTR LincolnLincoln, United StatesContact: Novo NordiskNo longer taking part
- My Preferred ResearchMiami, United StatesContact: Novo NordiskNo longer taking part
- New Horizon Research CenterMiami, United StatesContact: Novo NordiskNo longer taking part
- Adult Medicine of Lake County, Inc.Mt. Dora, United StatesContact: Novo NordiskNo longer taking part
- Southern NH Diabetes and Endo_NashuaNashua, United StatesContact: Novo NordiskNo longer taking part
- Clinical Research AssociatesNashville, United StatesContact: Novo NordiskNo longer taking part
- Tidewater Physicians Multispecialty GroupNewport News, United StatesContact: Novo NordiskNo longer taking part
- Alliance for Multispec ResNewton, United StatesContact: Novo NordiskNo longer taking part
- MedStar Health Research InstituteOlney, United StatesContact: Novo NordiskNo longer taking part
- Desert Oasis Hlthcr Med GroupPalm Springs, United StatesContact: Novo NordiskNo longer taking part
- Endo And Metab ConsRockville, United StatesContact: Novo NordiskNo longer taking part
- Northeast Clinical Research of San AntonioSan Antonio, United StatesContact: Novo NordiskNo longer taking part
- Pinnacle Clinical ResearchSan Antonio, United StatesContact: Novo NordiskNo longer taking part
- Diabetes & Endo Treatment SpecSandy City, United StatesContact: Novo NordiskNo longer taking part
- South Dakota Urban Indian HealthSioux Falls, United StatesContact: Novo NordiskNo longer taking part
- PHC AccelacareStatesville, United StatesContact: Novo NordiskNo longer taking part
- True Blue Clinical ResearchTampa, United StatesContact: Novo NordiskNo longer taking part
- Iowa Diab & Endo Res CenterWest Des Moines, United StatesContact: Novo NordiskNo longer taking part
- Southgate Medical Group, LLPWest Seneca, United StatesContact: Novo NordiskNo longer taking part
- Great Lakes Medical ResearchWestfield, United StatesContact: Novo NordiskNo longer taking part
- Encore Medical Research of WestonWeston, United StatesContact: Novo NordiskNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Novo Nordisk A/S
- Trial code
- NCT07931599EU 2026-525474-20-00
- Record updated
- 12 November 2026
- Original description
The study is testing zenagamtide in participants with type 2 diabetes. The purpose of this clinical study is to find out if zenagamtide is safe and effective for treating people who have type 2 diabetes. Participants will either get zenagamtide or semaglutide. Which treatment participants get is decided by chance. Zenagamtide is a new medicine that doctors cannot prescribe yet, but it has been tested in humans before.Read full original descriptionShow less
Efficacy and Safety of Zenagamtide s.c. Once Weekly Compared to Semaglutide s.c. Once Weekly at Lower Dose Levels in Participants With Type 2 Diabetes Inadequately Controlled on Metformin, SGLT2i, or Both
The study is testing zenagamtide in participants with type 2 diabetes. The purpose of this clinical study is to find out if zenagamtide is safe and effective for treating people who have type 2 diabetes. Participants will either get zenagamtide or semaglutide. Which treatment participants get is decided by chance. Zenagamtide is a new medicine that doctors cannot prescribe yet, but it has been tested in humans before.
Inclusion: Male or female (sex assigned at birth, inclusive of all gender identities); Age 18 years or above at the time of signing the informed consent; Diagnosed with type 2 diabetes (T2D) greater than or equal to (≥ )180 days before screening; On stable daily dose(s) of metformin, SGLT2 (sodium-glucose cotransporter 2) inhibitor, or both (at effective or maximum tolerated dose as judged by the investigator) prior to screening.
Exclusion: Myocardial infarction, stroke, transient ischaemic attack or hospitalisation for unstable angina pectoris within 60 days before screening; Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria before screening. However, insulin treatment for gestational diabetes is allowed as well as short term insulin treatment for a maximum of 14 consecutive days. However, insulin treatment for gestational diabetes or short-term insulin treatment for a maximum of 14 consecutive days is allowed; Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP-1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment) or amylin analogues before screening; Participant with diabetic retinopathy or maculopathy who received treatment with retinal photocoagulation, vitrectomy or anti-Vascular Endothelial Growth Factor (anti-VEGF) within 180 days before screening or are expected to require treatment within 180 days after screening. Diabetic retinopathy or maculopathy must be verified by an eye examination performed within 90 days before screening or in the period between screening and randomisation; Chronic heart failure classified as being in New York Heart Association (NYHA) Class IV at screening; Female who is pregnant, breast-feeding or intends to become pregnant or is of childbearing potential and not using adequate contraceptive method; Planned coronary, carotid or peripheral artery revascularisation.